Join

Compare · ELV vs NTRA

ELV vs NTRA

Side-by-side comparison of Elevance Health Inc. (ELV) and Natera Inc. (NTRA): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both ELV and NTRA operate in Medical Specialities (Health Care), so they compete in similar markets.
  • ELV is the larger of the two at $90.24B, about 2.9x NTRA ($30.84B).
  • Over the past year, ELV is up 6.7% and NTRA is up 31.2% - NTRA leads by 24.6 points.
  • NTRA has been more active in the news (16 items in the past 4 weeks vs 3 for ELV).
  • NTRA has more recent analyst coverage (25 ratings vs 23 for ELV).
PerformanceELV+6.68%NTRA+31.25%
2025-06-09+0.00%2026-06-05
MetricELVNTRA
Company
Elevance Health Inc.
Natera Inc.
Price
$415.68+1.52%
$215.31-3.06%
Market cap
$90.24B
$30.84B
1M return
+10.97%
+0.14%
1Y return
+6.68%
+31.25%
Industry
Medical Specialities
Medical Specialities
Exchange
NYSE
NASDAQ
IPO
2015
News (4w)
3
16
Recent ratings
23
25
ELV

Elevance Health Inc.

Elevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.

NTRA

Natera Inc.

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.

Latest ELV

Latest NTRA